According to BioPorto's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.94494. At the end of 2023 the company had a P/E ratio of -13.1.
Year | P/E ratio | Change |
---|---|---|
2023 | -13.1 | 40.8% |
2022 | -9.28 | -21.13% |
2021 | -11.8 | -12.66% |
2020 | -13.5 | 128.22% |
2019 | -5.90 | -62.93% |
2018 | -15.9 | 5.79% |
2017 | -15.0 | 21.8% |
2016 | -12.4 | -76.93% |
2015 | -53.6 | 248.59% |
2014 | -15.4 | 207.27% |
2013 | -5.00 | -74.47% |
2012 | -19.6 | -5.56% |
2011 | -20.7 | -10.19% |
2010 | -23.1 | 34.27% |
2009 | -17.2 | 27.74% |
2008 | -13.5 | 17.63% |
2007 | -11.4 | 88.8% |
2006 | -6.06 | -24.23% |
2005 | -8.00 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.